Advances in the Inhibitors of Janus Kinase

@article{Jiang2014AdvancesIT,
  title={Advances in the Inhibitors of Janus Kinase},
  author={Junhang Jiang and Xiaoying Wang and Yv Zhang and Yi Jin and Jun Lin},
  journal={Medicinal Chemistry},
  year={2014},
  volume={4},
  pages={540-548}
}
The janus kinases (JAKs) comprise an important class of non-receptor protein tyrosine kinases. Cytokine and receptor binding can cause the activation of JAKs, and then activate the "signal transcripts and transcriptional activator”, making JAK enter the nucleus to induce target gene expression. JAKs regulate inflammatory diseases, bone marrow hyperplasia and a variety of malignant tumours. Using JAKs inhibitors as the therapy for organ transplantation and immune disease has a very important… 
4 Citations

Figures and Tables from this paper

A novel approach in treatment of rheumatoid arthritis: Janus kinase inhibitors

Janus kinase (JAK) inhibitors are a new class of drugs that inhibit JAK enzymes, which are the main signal transducers for the majority of cytokines, growth factors, and interferons. These drugs work

Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases

The necessary steps for preparing the drug using two alternative routes for Baricitinib for the treatment of rheumatoid arthritis are described.

The Exploration of Chirality for Improved Druggability within the Human Kinome.

The role of chirality to improve kinome druggability is explored and will serve as a resource for pioneering kinase inhibitor development to address current therapeutic needs.

Baricitinib : A 2018 Novel FDA-Approved Small l l i iti i

  • 2019

References

SHOWING 1-10 OF 58 REFERENCES

Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.

The JAK pathways, the structure, function, and activation of the JAK enzymes are reviewed followed by a detailed look at theJAK inhibitors currently in the clinic or approved for these indications.

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.

The use of structural biology in Janus kinase targeted drug discovery.

Recent advances in understanding the druggable structure and function of the Janus kinases are reviewed, with a focus on the structural biology of the Jak kinase domain and how these advances impact the development of Jak-targeted therapeutics.

The JAK kinases: not just another kinase drug discovery target.

  • A. Wilks
  • Biology
    Seminars in cell & developmental biology
  • 2008

Investigational Janus kinase inhibitors

Janus kinase-signal transducer and activator of transcription pathway Dysregulation is central to the pathophysiology of myeloproliferative neoplasms and small molecule inhibitors of JAK family members are currently under investigation for the treatment of MPN.

Janus kinases: components of multiple signaling pathways

It has been found that JAK kinase function is required for optimal activation of the Src-kinase cascade, the Ras-MAP kinase pathway, the PI3K-AKT pathway and STAT signaling following the interaction of cytokine/interferon receptors with their ligands.

The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.

Concomitant Inhibition of Janus Kinase 3 and Calcineurin-Dependent Signaling Pathways Synergistically Prolongs the Survival of Rat Heart Allografts1

It is reported that AG-490 significantly prolonged allograft survival, but also acted synergistically when used in combination with the signal 1 inhibitor cyclosporin A, but not the signal 3 inhibitor, rapamycin.

Janus Kinase (Jak) Subcellular Localization Revisited

The hypothesis that cytokine receptor·Janus kinase complexes can be regarded as receptor tyrosine kinases is supported by the data observed, which show that Jak1 remains a membrane-localized protein after cytokine stimulation.
...